AVTR at a glance
Avantor Inc (AVTR, SEC CIK 1722482) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on July 29, 2026, an 8-K current report on September 21, 2026 and Form 4 insider filings as recently as September 23, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Avantor Inc (AVTR) reported revenue of $6.6 billion (down 3.4% from FY2024) and a net loss of $530.2 million. Diluted EPS was -$0.78.
- As of June 30, 2026, 35 institutional investment managers tracked by SignalX reported holding Avantor Inc (AVTR) shares worth $2.6 billion in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by LUCIER GREGORY T on May 8, 2026 of 10,000 shares at $8.32 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $6.6B
- −3.4% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 35 funds
- $2.6B · +1 vs prior quarter
- Latest 10-Q
- Jul 29, 2026
- Quarterly report
SignalX for AVTR
Don't miss the next AVTR filing
- Alerts as it files. A push when AVTR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AVTR, by share count.
- Ask anything. An AI agent that reads every AVTR filing and answers with sources.
AVTR alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Garner Todd W | A | Sep 21, 2026 | 138,632 | - |
| Garner Todd W | A | Sep 21, 2026 | 49,688 | - |
| Ligner Emmanuel | F | Aug 18, 2026 | 29,803 | $13.33 |
| Hankamer Brittany | F | Aug 14, 2026 | 181 | $13.66 |
| Eck Steven W | F | Jul 31, 2026 | 1,385 | $13.78 |
| Sokenu Claudius | F | Jul 24, 2026 | 1,201 | $11.44 |
| Walker Corey | F | Jun 21, 2026 | 3,010 | $9.58 |
| LUCIER GREGORY T | Buy | May 8, 2026 | 10,000 | $8.32 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $6.8B | $6.6B |
| Gross Profit | - | $2.3B | $2.1B |
| Operating Income | - | $1.1B | -$246.2M |
| Net Income | - | $711.5M | -$530.2M |
| Gross Margin | - | 33.6% | 32.7% |
| Op. Margin | - | 16.0% | -3.8% |
| Net Margin | - | 10.5% | -8.1% |
| Balance Sheet | |||
| Total Assets | $13.0B | $12.1B | $11.8B |
| Equity | - | $6.0B | $5.6B |
| ROE | - | 11.9% | -9.5% |
| Per Share | |||
| EPS | - | $1.04 | $-0.78 |
| Cash Flow | |||
| Operating CF | - | $840.8M | $623.8M |
| CapEx | $146.4M | $148.8M | $128.8M |
Source: XBRL data in Avantor Inc (AVTR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate AVTR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 35 | $2.65B |
| Q1 2026 | 34 | $1.89B |
| Q4 2025 | 33 | $2.84B |
| Q3 2025 | 35 | $3.02B |
| Q2 2025 | 33 | $3.30B |
| Q1 2025 | 29 | $2.42B |
| Q4 2024 | 26 | $2.80B |
| Q3 2024 | 22 | $1.57B |
- AQR Capital Management+6.76M (+139%)
- Invesco Ltd+5.81M (+72%)
- BlackRock+4.58M (+7%)
- Bank of America Corp+3.92M (+55%)
- Dimensional Fund Advisors+3.52M (+21%)
- D.E. Shaw & Co−3.54M (-27%)
- Millennium Management−1.68M (-69%)
- BNY Mellon−297.8K (-7%)
- Citadel Advisors LLC−170.4K (-30%)
- Raymond James Financial−97.5K (-10%)
- Citizens Financial Group+23.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 247 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AVTR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
Related Health Care companies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- A · Agilent TechnologiesLaboratory Analytical Instruments
- ALMR · Alamar Biosciences IncLaboratory Analytical Instruments
- BIO · Bio-rad Laboratories IncLaboratory Analytical Instruments
- BRKR · Bruker CorpLaboratory Analytical Instruments
- CTKB · Cytek Biosciences, Inc.Laboratory Analytical Instruments
- EYPT · EyePoint, Inc.Laboratory Analytical Instruments
- ILMN · Illumina IncLaboratory Analytical Instruments
AVTR SEC filings: frequently asked questions
Which institutions hold AVTR stock?
As of June 30, 2026, the largest Avantor Inc (AVTR) holders among the 13F filers tracked by SignalX were BlackRock ($695.8 million), Vanguard Portfolio Management LLC ($310.3 million), Vanguard Capital Management LLC ($304.9 million), State Street Corp ($213.6 million), Dimensional Fund Advisors ($202.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was AVTR's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Avantor Inc (AVTR) reported revenue of $6.6 billion (down 3.4% from FY2024) and a net loss of $530.2 million. Diluted EPS was -$0.78. The figures come from the XBRL data in the 10-K.
What are the latest AVTR SEC filings?
Avantor Inc (AVTR) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on July 29, 2026, an 8-K current report on September 21, 2026 and a Form 4 insider filing on September 23, 2026.
What is AVTR's SEC CIK number?
Avantor Inc (AVTR)'s SEC Central Index Key (CIK) is 1722482. EDGAR lists every AVTR filing under that number.
Ask anything about AVTR
The research agent reads AVTR's filings, financials, insider trades and 13F holders, then answers with sources.